Angelo Pirozzi: Update on FIGHT-202

Angelo Pirozzi, Research Fellow at Mayo Clinic, shared on X:

“Update on FIGHT-202

145 patients with pretreated advanced CCA and FGFR2 alterations received pemigatinib

Median follow-up 45 mos For FGFR2 fusions:

• ORR 37%
  
• mDOR 9.1 mos
  
• mPFS 7.0 mos
  
• mOS 17.5 mos
  
• 10.2% TEAEs led to discontinuation.“

Read further.
Source: Angelo Pirozzi/X